📄 Redirect examination of Dr. John Gerdes (afternoon) — Monday, August 7, 1995
Address:
C:\DEPT103\CRIMINAL\1995\AUG\7\REDIRECT-EXAMINATION-OF-DR-JOH.DOC
TRIAL
▲ Day 130 of 167

Redirect examination of Dr. John Gerdes (afternoon)

Witness: Dr. John Gerdes
Examiner: Barry Scheck
Called by: Defense • Date: Monday, August 7, 1995 • Utterances: 241
Scheck uses redirect to rehabilitate Dr. Gerdes's core contamination opinions after Clarke's cross-examination. Gerdes reaffirms that D1S80 results on the Rockingham glove wrist area carry substantial cross-contamination risk from Yamauchi's sample-handling error, that the LAPD's proficiency test errors would have caused wrongful inclusions and exclusions, and that the lab's failure to recognize their chemical hood was not a laminar flow hood reflects dangerous incompetence. The NRC report is introduced to validate Gerdes's view that nonexpert labs misusing PCR kits are precisely the problem the scientific community warned about.
1 THE COURT:

All right. Thank you, ladies and gentlemen. Please be seated. Dr. Gerdes, would you resume the witness stand, please.

John Gerdes, the witness on the stand at the time of the lunch recess, resumed the stand and testified further as follows: THE COURT: All right. Good afternoon again, doctor.

2 DR. GERDES:

Good afternoon.

3 THE COURT:

You are reminded, sir, you are still under oath. Mr. Scheck, you may continue with your redirect.

4 MR. SCHECK:

Thank you, your Honor. Good afternoon, ladies and gentlemen of the jury.

THE JURY: Good afternoon.

REDIRECT EXAMINATION (RESUMED) BY MR. SCHECK

5 MR. SCHECK:

Dr. Gerdes, let me discuss with you briefly the results on the glove. And I'd like to show you first the results of DNA analysis, Rockingham glove, which is Prosecution's 272. Now, Dr. Gerdes, Mr. Clarke asked you about the results from RFLP tests that were consistent with Nicole Brown Simpson and Ronald Goldman on various areas of the glove, specifically G1, G2, G3, G4, G9, that were confirmed by RFLP--well, G4--I'm sorry--that were confirmed by RFLP tests, correct?

6 DR. GERDES:

Yes.

7 MR. SCHECK:

All right. G11, G10 and G13 are the D1S80 results in the wrist area of the glove which produced results with Mr. Simpson; is that correct?

8 DR. GERDES:

That's what they state, yes.

9 MR. SCHECK:

Are there any RFLP results confirming that result?

10 DR. GERDES:

No.

11 MR. SCHECK:

Now, putting on the--this is Defense 1186, Mr. Yamauchi's diagram of the glove found at Rockingham. Dr. Gerdes, is this the--this diagram reflect what your understanding is of the--what Mr. Yamauchi did on the morning of June 14th between 9:00 and 10:00 o'clock when he handled the glove from Rockingham after having handled Mr. Simpson's reference sample where he had that incident where the--took off the top and the blood went through the chemex and onto his glove?

12 MR. CLARKE:

Objection. Leading.

13 THE COURT:

Sustained.

14 MR. SCHECK:

Well, as far as the D1S80 results from the wrist area of the glove, what is your opinion as to the acceptable risks of cross-contamination with respect to those results?

15 MR. CLARKE:

Objection. No foundation.

16 THE COURT:

Overruled.

17 DR. GERDES:

They were handled the same time or shortly after Mr. Simpson's reference sample was handled. The testimony states that the sample had leaked, and under those circumstances, it represents substantial risk that contamination could have happened.

18 MR. SCHECK:

Are the D1S80 results in terms of the amount of DNA found in the wrist area of that glove consistent with cross-contamination from the sample handling error?

19 DR. GERDES:

Yes.

20 MR. CLARKE:

Objection. Calls for speculation.

21 THE COURT:

Sustained.

22 MR. CLARKE:

Move to strike the answer.

23 THE COURT:

The answer is stricken.

24 MR. SCHECK:

On the basis of the amounts of DNA in those D1S80 tests and your review of the procedures that Mr. Yamauchi used, do you believe--what do you believe about the level of risk of cross-contamination with respect to those results?

25 MR. CLARKE:

Objection. No foundation. Calls for speculation.

26 THE COURT:

Overruled.

27 DR. GERDES:

There's substantial risk at cross-contamination under those circumstances.

28 MR. SCHECK:

This is Defense 1308, testing results, Nicole Brown Simpson and Ronald Goldman reference samples. Now, Mr. Clarke asked you a series of questions about controls and evidence of cross-contamination from the way that samples were handled in the evidence processing room on June 14th and June 15th. Do you recall those?

29 DR. GERDES:

The questions regarding--yes.

30 MR. SCHECK:

All right. With respect to cross-contamination occurring in the handling of samples by Mr. Yamauchi on June 15th, specifically item 12, the last blood sample collected from the foyer in Mr. Simpson's home and Nicole Brown Simpson reference sample and Ron Goldman reference sample, do you believe that the results shown on this board are consistent with cross-contamination that was then retyped in two different laboratories, Cellmark and DOJ?

31 MR. CLARKE:

Objection. No foundation. Calls for speculation and leading.

32 THE COURT:

Overruled.

33 DR. GERDES:

Yes.

34 MR. SCHECK:

Are the results from this board part of the basis for your opinion that there were unacceptable risks of contamination in the way Mr. Yamauchi handled those samples on June 14th and June 15th?

35 DR. GERDES:

Yes. These results were consistent with evidence that cross-contamination actually happened.

36 MR. SCHECK:

Now, Dr. Gerdes, you were asked--let me show you what is--this is Defense 1297, a chart depicting runs and strips May through July of 1994, run contamination, strip contamination and/or artifacts. Now, Dr. Gerdes, you were asked quite a number of--you were asked quite a number of questions on cross examination about the distinction you made when analyzing strips where you put--you indicated there were strip contamination and/or artifacts. You recall those?

37 DR. GERDES:

I do.

38 MR. SCHECK:

And I call your attention to Prosecution's 566. Do you see that?

39 DR. GERDES:

Yes.

40 MR. SCHECK:

What is that strip?

41 DR. GERDES:

And these are a series of strips that the Prosecution showed to demonstrate the weak 1.1 and I believe in reference to discussing the DX allele.

42 MR. SCHECK:

All right. And this is the 1.1 in the presence of the 1, correct?

43 DR. GERDES:

Correct.

44 MR. SCHECK:

And it was your--was it your testimony that in looking at that 1, you could not tell if that was--that is, the 1.1's were contaminants or artifacts?

45 DR. GERDES:

That's correct. Under this circumstance, you can't really tell if that's an artifact or contaminant.

46 MR. SCHECK:

Is that why you made the distinction when you--

47 DR. GERDES:

Yes.

48 MR. SCHECK:

--identified the strips?

49 DR. GERDES:

Yes. In terms of the strips, that's the reason why I did not really try to differentiate between the two because in many--situations such as this, you can't tell.

50 MR. SCHECK:

Now, what relation--what relationship does a result such as depicted on 566, where you can't tell if it's a contaminant or artifact, have in terms of making erroneous typings?

51 MR. CLARKE:

Objection. Vague.

52 THE COURT:

Sustained. Rephrase the question.

53 MR. SCHECK:

What is--why is it--what are the problems you see in the results such as depicted on 566 in terms of making an interpretation of the strip?

54 DR. GERDES:

Well, on--if you look at the strip that has the 1.1 allele, the weak 1.1 allele, if this were a crime scene specimen, the interpretation of that would be that particular item where type is a 1.2, 1.2 because you can see the 1.2 signal here is dark and the 1 is dark; and for that reason, this would be probably typed as a 1.2, 1.2. but because of the weak 1.1, most likely, they would express the fact that that was present there and visible. And so it would be a 1.2, 1.2 consistent with a contributor of--with a 1.1. so it would be consistent with an individual with a 1.1, 1.1 or an individual with a 1.1, 1.2. so that obviously makes this a--that artifact has a potential of falsely accusing an individual who's a 1.1, 1.2 when in fact typing results is from a 1.2, 1.2.

55 MR. CLARKE:

Excuse me. Objection. Calls for speculation. No foundation.

56 THE COURT:

Overruled.

57 MR. SCHECK:

Well, doctor, let me see if I can try to put this in as plain as English as I can. Is the existence of a faint dot like that in a mixture, can that cause an error?

58 DR. GERDES:

Yes. And it doesn't matter if it's an artifact or a real contaminant. Either way, it can cause an error.

KEY QUOTE
59 MR. SCHECK:

Are dots of that intensity similar to the 1.3 dot we saw before on item 31 of the Bronco console?

60 DR. GERDES:

Yes.

61 MR. SCHECK:

We can turn off the--this is Defense 1295.

62 MR. SCHECK:

Dr. Gerdes, you recall Mr. Clarke asking you questions about whether or not two analysts ever did samples on the same day in your calculation of runs? Remember that?

63 DR. GERDES:

I remember that.

64 MR. SCHECK:

Remember he asked you if you were sure about that?

65 DR. GERDES:

Yes.

66 MR. SCHECK:

All right. Have you rechecked your data?

67 DR. GERDES:

Yes.

68 MR. SCHECK:

Are you sure that two analysts didn't do or--strips on the same day?

69 DR. GERDES:

Yes.

70 MR. SCHECK:

Now, do these runs, as you recorded them by month, represent contamination, definite contamination on the day all the strips were run?

71 DR. GERDES:

Yes. At this point, they're definite contamination because I take all of the strips on a given date and I can look in the context of what's in that--in all of those strips so that you can confirm with one strip whether you're seeing the same thing in more than one strip.

72 MR. SCHECK:

So this chart represents definite contamination, no ambiguity about artifacts as far as you're concerned?

73 DR. GERDES:

At this point, that's correct.

74 MR. SCHECK:

By the standards that you were familiar with to accredit DNA laboratories, given this level of contamination in runs, in your opinion, would the Los Angeles Police Department be allowed to operate?

75 MR. CLARKE:

Objection. No foundation. Calls for speculation.

76 THE COURT:

Sustained.

77 MR. SCHECK:

Are you familiar with the standards used to regulate DNA laboratories in clinical applications?

78 DR. GERDES:

Yes.

79 MR. SCHECK:

By those standards, would a lab be allowed to operate with this level of contamination?

80 MR. CLARKE:

Same objection. Same grounds.

81 THE COURT:

Sustained.

82 MR. SCHECK:

Now, Dr. Gerdes, you were--excuse me. You were asked a whole series of questions by Mr. Clarke in regard to the use of PCR in other clinical applications. Do you recall those?

83 DR. GERDES:

I do.

84 MR. SCHECK:

Are you against the use of PCR technology per se?

85 DR. GERDES:

No, I'm not.

86 MR. SCHECK:

Do you use it yourself?

87 DR. GERDES:

I do.

88 MR. SCHECK:

Have you developed PCR tests yourself such as the CNV test?

89 DR. GERDES:

Yes.

90 MR. SCHECK:

If PCR base test is reliable for some clinical applications, does that mean it is reliable for all others?

91 DR. GERDES:

No.

92 MR. SCHECK:

Does that mean it is reliable for use on forensic samples?

93 DR. GERDES:

No.

94 MR. SCHECK:

Does the reliability of a PCR base technique depend on the standards and the quality of the lab that's using the technique?

95 DR. GERDES:

Absolutely.

96 MR. CLARKE:

Objection. Leading.

97 THE COURT:

Overruled.

98 MR. SCHECK:

Does it depend on the nature of the samples being tested?

99 DR. GERDES:

Yes.

100 MR. SCHECK:

Does the fact that the DQ-Alpha kit is sold commercially with the user guide mean that this technique is reliable for all forensic uses by all forensic laboratories?

101 DR. GERDES:

No.

102 MR. SCHECK:

Doctor, have you read--Mr. Clarke asked you a whole series of questions about kits. Do you recall those?

103 DR. GERDES:

Yes.

104 MR. SCHECK:

All right. Do you--are you familiar with the discussion in the NRC report with respect to the kits that were used in this case?

105 DR. GERDES:

Yes, I am.

106 MR. SCHECK:

Do you rely on that in formulating your opinions?

107 DR. GERDES:

Yes.

108 MR. SCHECK:

Your Honor, we would like to--I've shown this to Mr. Clarke. I'd like to put a slide on the screen.

109 THE COURT:

Proceed.

110 MR. SCHECK:

Would the Court like to see it first? I'll mark this in a second.

111 THE COURT:

Mrs. Robertson, what is Defense next in order?

112 THE CLERK:

1312.

113 MR. SCHECK:

1312?

114 MR. CLARKE:

I'm sorry. Could we have a moment before it's displayed, your Honor?

115 THE COURT:

Yes.

116 (Deft's 1312 for id = slide)
117 MR. SCHECK:

Let me just--it may be faster if I just read this.

118 THE COURT:

You want to put it on the elmo? A little small?

119 MR. SCHECK:

I included two extra sentences that I told him I wouldn't include.

120 THE COURT:

All right.

121 MR. SCHECK:

Do you agree with the following statement in the NRC report? "One commercial kit for forensic PCR analysis has been marketed." Now, let me just stop there. What kit is that?

122 DR. GERDES:

At that time, that was the DQ-Alpha kit.

123 MR. SCHECK:

"Other kits will probably be ready for commercial market soon." What kits would those be?

124 DR. GERDES:

Polymarker and the D1S80.

125 MR. SCHECK:

"The committee sees a potential for introduction of unreliable kits and the misuse of kits. The existence of a kit suggests ease of use and low chance of technical error. The committee believes that nonexpert laboratories will run a significant chance of error in using kits." Do you agree with that?

126 DR. GERDES:

I do.

127 MR. SCHECK:

What is your opinion about this--this--what the NRC said and the LAPD laboratory in this case?

128 MR. CLARKE:

Objection. Vague.

129 THE COURT:

Overruled.

130 DR. GERDES:

I believe that the situation we've seen here is precisely what the NRC is talking about here.

KEY QUOTE
131 MR. SCHECK:

And why is that?

132 MR. CLARKE:

Excuse me. Objection. Calls for speculation.

133 THE COURT:

Overruled.

134 MR. SCHECK:

Why is that?

135 DR. GERDES:

Because the LAPD has made substantial errors and have failed to see the subtleties that are critical to interpretation of this kind of testing due to the fact that they were inexperienced.

KEY QUOTE
136 MR. SCHECK:

So just the fact that one has a kit doesn't mean that you can apply it correctly?

137 DR. GERDES:

That's correct.

138 MR. SCHECK:

Dr. Gerdes, very quickly, you were asked a lot of questions about proficiency tests. Does it make a difference in proficiency tests that the tests involve samples that are just like the ones that you deal with in casework?

139 MR. CLARKE:

Objection. Asked and answered.

140 MR. SCHECK:

On redirect? All right. Just forget it all. I think you're right.

141 THE COURT:

It's a point we've made.

142 MR. SCHECK:

It's a point--well, you're right. A few times.

143 MR. SCHECK:

All right. Do you recall Mr. Clarke asked you about the laminar flow hood in your--and the records you made in your notes, correct?

144 DR. GERDES:

I remember that.

145 MR. SCHECK:

All right. Can you please explain when you realized that the LAPD did not have a laminar flow hood?

146 DR. GERDES:

That was on my second visit. The first visit, I didn't--I hadn't noticed that.

147 MR. SCHECK:

Is there any question in your mind that that hood is not a laminar flow hood?

148 DR. GERDES:

None whatsoever.

149 MR. SCHECK:

Is the fact that it's not a laminar flow hood, does that create dangers of contamination in the laboratory?

150 DR. GERDES:

Absolutely.

151 MR. SCHECK:

Is a laminar flow hood a fundamental in terms of taking precautions against contamination in a DNA laboratory?

152 DR. GERDES:

Yes.

153 MR. SCHECK:

Is it disturbing to you that the Los Angeles Police Department DNA laboratory did not--was not aware that its hood was not a laminar flow hood?

154 MR. CLARKE:

Objection. Leading, argumentative.

155 THE COURT:

Sustained.

156 MR. SCHECK:

What is the significance of this hood not being a laminar flow hood in terms of the level of competence and knowledge of the personnel at the LAPD DNA laboratory?

157 MR. CLARKE:

Objection. Argumentative, no foundation.

158 THE COURT:

Sustained. Rephrase the question.

159 MR. SCHECK:

All right. In terms of the ability--based on your experience as a DNA laboratory director, what is your opinion about laboratory personnel being unaware of the nature of the hood they're using when processing samples?

160 MR. CLARKE:

Same objection. Same ground.

161 THE COURT:

Sustained.

162 MR. SCHECK:

In terms of the reliability of the procedures used at the Los Angeles Police Department in handling DNA samples, what in your judgment is the significance of their failure to know that their hood was not a laminar flow hood?

163 MR. CLARKE:

Same objection. Same ground.

164 THE COURT:

Sustained.

165 MR. SCHECK:

Which--the ground is conclusion?

166 THE COURT:

The issue here is, what's the benefit to having a laminar flow hood versus what's there. That's the real issue.

KEY QUOTE
167 MR. SCHECK:

Thank you.

168 MR. SCHECK:

What's the benefit of having a laminar flow hood versus a chemical hood?

169 MR. SCHECK:

Thank you, your Honor.

170 DR. GERDES:

The laminar flow hood is designed to--for the applications where you're concerned about either contaminating an item or being contaminated by that item. That's what they're designed for. That's what their purpose is. A chemical fume hood was designed for an entirely different purpose which is not appropriate for handling those kind of samples.

171 MR. SCHECK:

If you're working in a DNA laboratory, in your opinion, is it important to know the difference between a chemical hood and a laminar flow hood?

172 MR. CLARKE:

Same objection. Same ground.

173 THE COURT:

Overruled.

174 DR. GERDES:

Yes, it's important.

175 MR. SCHECK:

Now, you were asked many questions on cross-examination concerning your conclusions about incorrect typing results by the Los Angeles Police Department personnel on mock validation studies and proficiency tests. Do you recall those?

176 DR. GERDES:

Yes, I do.

177 MR. SCHECK:

All right. First I'd like to address the mock validation studies.

178 MR. SCHECK:

Excuse me, your Honor. I'm sorry.

179 (Brief pause.)
180 MR. SCHECK:

Now, I'm going to show you some slides, but first, I'd like to just refresh everybody's recollection with showing the raw data. The first mock validation study was one--if you can pull back--done by Mr. Yamauchi on September 9th. Do you recall that?

181 DR. GERDES:

Yes.

182 MR. SCHECK:

And this is where he was typing a vaginal swab with an epithelial fraction--

183 DR. GERDES:

Yes.

184 MR. SCHECK:

--and a sperm fraction?

185 DR. GERDES:

Yes.

186 MR. SCHECK:

All right. And you testified he got an incorrect typing result?

187 DR. GERDES:

That's correct.

188 MR. SCHECK:

Then the second one was the same set of samples typed on September 21st by Erin Riley. You recall that?

189 DR. GERDES:

I do.

190 MR. SCHECK:

Now, your Honor--

191 THE COURT:

And, Mr. Harris, which exhibits are those?

192 MR. SCHECK:

This is--first one is--561 is the September 9th and 562 is the September 21st.

193 THE COURT:

Thank you.

194 MR. SCHECK:

All right. Now, I would like to turn to the slide marked--

195 MR. SCHECK:

What's the Defendant's next in order?

196 THE CLERK:

1313.

197 MR. SCHECK:

1314?

198 THE CLERK:

1313.

199 MR. SCHECK:

I can't hear.

200 THE COURT:

1313.

201 MR. SCHECK:

1313. And I guess we'll call this A-1.

202 (Deft's 1313-A through 1313-C for id = slides)
203 MR. SCHECK:

Now, Dr. Gerdes, what does this represent?

204 DR. GERDES:

On the far left, it represents the correct type for this particular mock validation specimen. So the little symbol on top there stands for the male fraction. The male fraction should be a 1.2, 1.3. the next one below the epithelial cell or the female fraction should be 1.2, 4.

205 MR. SCHECK:

What was the LAPD type?

206 DR. GERDES:

On the sperm fraction, the LAPD found a 1.2, 4.

207 MR. SCHECK:

And is that a correct type in your opinion?

208 DR. GERDES:

No. You can see it does not match the anticipated male pattern that should have been there. The 1.2, 1.3 is not equal to 1.2, 4.

209 MR. SCHECK:

Can we have the next slide, please.

210 MR. SCHECK:

All right. Tell us what this represents in terms of the consequences of that mistyping.

211 DR. GERDES:

What that means is the--given the LAPD type of 1.2, 4, if the suspect were a 4.4, a 1.2, 4 or a 1.2, 1.2, all of those individuals would be included as having matched that male fraction.

212 MR. SCHECK:

Is that one of the reasons you think this is a mistake?

213 DR. GERDES:

Yes. Because these suspects would have been wrongly accused.

KEY QUOTE
214 MR. SCHECK:

Next slide.

215 MR. SCHECK:

What does this represent?

216 DR. GERDES:

Well, since the true and correct type was missed, the 1.2, 1.3 was missed, the true perpetrator would not have been recognized and so he would have been excluded falsely. So, again, that's an error.

217 MR. SCHECK:

The second slide I should note was B and this third slide is C.

218 THE COURT:

That's correct.

219 MR. SCHECK:

And is this the--are these among the reasons that you believe that these were erroneous typings?

220 DR. GERDES:

Yes.

221 MR. SCHECK:

Is this one reason you disagree with the statement in the validation study that no incorrect results were observed?

222 DR. GERDES:

Yes.

223 MR. SCHECK:

All right. I'd like now to turn to the next--

224 MR. SCHECK:

You also discussed two other errors by--in proficiency tests. First one just to show the raw data--

225 MR. SCHECK:

Could you pull back a little bit, please, so we can see the date.

226 MR. SCHECK:

Now, what was--what were these set of samples on July 14th?

227 DR. GERDES:

These were proficiency samples that were part of--well, part of a proficiency test.

228 MR. SCHECK:

And what does that mean? Where do the samples come from?

229 DR. GERDES:

They come from an external source.

230 MR. SCHECK:

All right. Are they supposed to have contaminants in them?

231 DR. GERDES:

No.

232 MR. SCHECK:

All right. And this was the run done by Erin Riley on 7-14-93?

233 DR. GERDES:

Correct.

234 MR. SCHECK:

Where you found an incorrect typing?

235 DR. GERDES:

That's correct.

236 MR. SCHECK:

All right. And is this the raw data for the--when she did it again on?

237 DR. GERDES:

She repeated it on 7-15.

238 MR. SCHECK:

Okay. Thank you.

239 MR. SCHECK:

Now, can we turn to the next set of slides I would ask be marked Defendant's 13--

240 THE COURT:

14.

241 MR. SCHECK:

1314. And ask slide no. 1 which we'll call 1314-A.

Temperature

tense

Key Quotes (5)

Dr. John Gerdes
the LAPD has made substantial errors and have failed to see the subtleties that are critical to interpretation of this kind of testing due to the fact that they were inexperienced.
Gerdes's most direct and sweeping indictment of LAPD lab competence, tying their specific errors to systemic inexperience rather than isolated mistakes.
Dr. John Gerdes
I believe that the situation we've seen here is precisely what the NRC is talking about here.
Links the authoritative National Research Council's own warning about kit misuse by nonexpert labs directly to the LAPD, lending institutional weight to Gerdes's critique.
Dr. John Gerdes
it doesn't matter if it's an artifact or a real contaminant. Either way, it can cause an error.
Neutralizes Clarke's cross-examination strategy of distinguishing artifacts from contamination — Gerdes argues the distinction is irrelevant to the risk of wrongful typing.
Dr. John Gerdes
these suspects would have been wrongly accused.
Plain-language summary of why the mock validation mistyping matters: real-world consequences of LAPD error would have been false accusations.
Lance A. Ito
The issue here is, what's the benefit to having a laminar flow hood versus what's there. That's the real issue.
Unusually, the judge intervenes to reframe Scheck's repeatedly-sustained question about the hood, effectively coaching Scheck on how to get the testimony in.

Evidence (10)

Prosecution's 272
DNA analysis results for the Rockingham glove
discussed — Scheck uses to highlight absence of RFLP confirmation for D1S80 wrist-area results matching Simpson
Defense 1186
Yamauchi's diagram of the Rockingham glove
referenced in leading question that was sustained; establishes handling timeline
Defense 1308
Testing results for Nicole Brown Simpson and Ronald Goldman reference samples
discussed — used to support contamination theory for item 12, confirmed by both Cellmark and DOJ
Defense 1297
Chart of LAPD PCR runs and strips May–July 1994 showing run/strip contamination and artifacts
discussed — Gerdes confirms these represent definite (not ambiguous) contamination events
Prosecution's 566
Strips showing weak 1.1 allele in presence of dominant 1 allele
discussed — Gerdes explains why faint dots like these (similar to item 31 Bronco console dot) can produce erroneous typings regardless of whether they are artifacts or contaminants
Defense 1312
Slide containing NRC report language on commercial PCR kits and risk of misuse by nonexpert laboratories
introduced — Gerdes agrees the NRC warning describes exactly what happened at LAPD
+ 4 more

Notable Exchanges (3)

Barry ScheckLance A. Ito
After three consecutive sustained objections to Scheck's attempts to elicit Gerdes's opinion on the significance of the LAPD not knowing their hood was not a laminar flow hood, Ito breaks in and tells Scheck exactly how to frame the question: 'The issue here is, what's the benefit to having a laminar flow hood versus what's there.' Scheck thanks the judge and gets the testimony in.
strategic/collaborative — judge provides roadmap for admissible question
Barry ScheckGeorge Clarke
Scheck introduces NRC slide (Defense 1312) but admits he included two extra sentences he had told Clarke he wouldn't include, prompting Clarke to request a moment before display. Scheck then offers to just read the relevant portion aloud.
mildly adversarial — minor gamesmanship acknowledged
Barry ScheckGeorge Clarke
Clarke objects 'asked and answered' to a question on proficiency test sample authenticity. Scheck immediately concedes — 'All right. Just forget it all. I think you're right' — and Ito confirms it's a point already made several times.
light/self-aware — Scheck acknowledges overreach

Light Moments (2)

Barry Scheck
Scheck admits he slipped extra NRC report sentences into Defense 1312 that he had promised Clarke to omit: 'I included two extra sentences that I told him I wouldn't include.'
Barry Scheck / Lance A. Ito
After multiple sustained objections on the laminar flow hood significance, Ito essentially writes the admissible question for Scheck, who responds with 'Thank you, your Honor' and immediately uses the judge's framing verbatim.

Credibility Attacks (3)

⚔ LAPD DNA Laboratory (Collin Yamauchi / Erin Riley)
documented error pattern — proficiency test failures and mock validation mistypings
Gerdes walks through Defense 1313 slides showing that LAPD's September 9th mock validation typing of a sperm fraction was incorrect (typed 1.2,4 instead of correct 1.2,1.3), with Gerdes explaining that the error would have both falsely accused innocent suspects and falsely excluded the true perpetrator.
⚔ LAPD DNA Laboratory
equipment ignorance — failure to distinguish chemical hood from laminar flow hood
Gerdes testifies without qualification that the LAPD hood is not a laminar flow hood, that this creates contamination risk, and that lab personnel not knowing the difference reflects on their competence — testimony the court struggled to allow in due to sustained argumentative/foundation objections.
⚔ LAPD DNA Laboratory
NRC institutional authority
Scheck uses the NRC report's own language warning that 'nonexpert laboratories will run a significant chance of error in using kits' and has Gerdes confirm the LAPD situation is 'precisely what the NRC is talking about.'

Objections

17 objections (9 sustained, 7 overruled)
Proceeding 7215 • 241 utterances • Defense witness
Criminal Trial
Department 103
⚖️ Start
📂 AUG 7, 1995 📄 Redirect examination of Dr. Jo
AUG 7, 1995 KRT DvH TD